Abstract
The under-representation of non-European cohorts in neurodegenerative disease genome-wide association studies (GWAS) hampers precision medicine efforts. Despite the inherent genetic and phenotypic diversity in these diseases, GWAS research consistently exhibits a disproportionate emphasis on participants of European ancestry. This study reviews GWAS up to 2022, focusing on non-European or multi-ancestry neurodegeneration studies. We conducted a systematic review of GWAS results and publications up to 2022, focusing on non-European or multi-ancestry neurodegeneration studies. Rigorous article inclusion and quality assessment methods were employed. Of 123 neurodegenerative disease (NDD) GWAS reviewed, 82% predominantly featured European ancestry participants. A single European study identified over 90 risk loci, compared to a total of 50 novel loci in identified in all non-European or multi-ancestry studies. Notably, only six of the loci have been replicated. The significant under-representation of non-European ancestries in NDD GWAS hinders comprehensive genetic understanding. Prioritizing genomic diversity in future research is crucial for advancing NDD therapies and understanding.
Highlights
Eighty-two percent of neurodegenerative genome-wide association studies (GWAS) focus on Europeans.
Only 6 of 50 novel neurodegenerative disease (NDD) genetic loci have been replicated.
Lack of diversity significantly hampers understanding of NDDs.
Increasing diversity in NDD genetic research is urgently required.
New initiatives are aiming to enhance diversity in NDD research.
If you do not see content above, kindly GO TO SOURCE.
Not all publishers encode content in a way that enables republishing at Neuro.vip.
This post is Copyright: Caroline Jonson,
Kristin S. Levine,
Julie Lake,
Linnea Hertslet,
Lietsel Jones,
Dhairya Patel,
Jeff Kim,
Sara Bandres‐Ciga,
Nancy Terry,
Ignacio F. Mata,
Cornelis Blauwendraat,
Andrew B. Singleton,
Mike A. Nalls,
Jennifer S. Yokoyama,
Hampton L. Leonard | June 22, 2024